- Home
- WWR vs CALC Comparison
WWR vs CALC Comparison
Compare WWR & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WWR
- CALC
- Stock Information
- Founded
- WWR 1977
- CALC 2011
- Country
- WWR United States
- CALC United States
- Employees
- WWR N/A
- CALC N/A
- Industry
- WWR Metal Mining
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- WWR Basic Materials
- CALC Health Care
- Exchange
- WWR Nasdaq
- CALC Nasdaq
- Market Cap
- WWR N/A
- CALC 22.9M
- IPO Year
- WWR N/A
- CALC N/A
- Fundamental
- Price
- WWR $0.59
- CALC $2.13
- Analyst Decision
- WWR Strong Buy
- CALC Strong Buy
- Analyst Count
- WWR 1
- CALC 2
- Target Price
- WWR $2.00
- CALC $14.50
- AVG Volume (30 Days)
- WWR 607.4K
- CALC 38.7K
- Earning Date
- WWR 08-13-2025
- CALC 08-11-2025
- Dividend Yield
- WWR N/A
- CALC N/A
- EPS Growth
- WWR N/A
- CALC N/A
- EPS
- WWR N/A
- CALC N/A
- Revenue
- WWR N/A
- CALC N/A
- Revenue This Year
- WWR N/A
- CALC N/A
- Revenue Next Year
- WWR N/A
- CALC N/A
- P/E Ratio
- WWR N/A
- CALC N/A
- Revenue Growth
- WWR N/A
- CALC N/A
- 52 Week Low
- WWR $0.45
- CALC $1.42
- 52 Week High
- WWR $1.32
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- WWR 58.04
- CALC 48.14
- Support Level
- WWR $0.59
- CALC $1.59
- Resistance Level
- WWR $0.63
- CALC $1.69
- Average True Range (ATR)
- WWR 0.03
- CALC 0.15
- MACD
- WWR -0.00
- CALC 0.01
- Stochastic Oscillator
- WWR 50.00
- CALC 46.51
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.